A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE

Jonsson F.; Siegel D.; Jagannath S.; Vij R.; Badros A.; Ou Y.; Claret L.; Kavalerchik E.; Bruno R.

首页> 外文期刊>Clinical Pharmacology and Therapeutics >A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE

【24h】

A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE

机译：单药卡培唑使用后复发/耐药性多发性骨髓瘤患者基于M蛋白水平的肿瘤生长抑制模型

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Clinical Pharmacology and Therapeutics》 |2014年第1期|共1页
作者
Jonsson F.; Siegel D.; Jagannath S.; Vij R.; Badros A.; Ou Y.; Claret L.; Kavalerchik E.; Bruno R.;
展开▼
作者单位

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类药理学;
关键词

相似文献

外文文献
中文文献
专利

1. A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE [J] . Jonsson F., Siegel D., Jagannath S., Clinical Pharmacology and Therapeutics . 2014,第Suppla1期

机译：单药卡培唑使用后复发/耐药性多发性骨髓瘤患者基于M蛋白水平的肿瘤生长抑制模型
2. Incidence and management of adverse events in patients with relapsed and/or refractory multiple myeloma receiving single-agent carfilzomib [J] . R Donald Harvey Clinical Pharmacology: Advances and Applications . 2014,第1期

机译：接受单剂卡非佐米治疗的复发和/或难治性多发性骨髓瘤患者的不良事件发生率和处理
3. From clinical trials to clinical practice: single-agent carfilzomib adverse events and their management in patients with relapsed and/or refractory multiple myeloma [J] . David S. Siegel Therapeutic advances in hematology. . 2013,第6期

机译：从临床试验到临床实践：单药卡非佐米不良事件及其在复发和/或难治性多发性骨髓瘤患者中的处理
4. Model-based angiogenic inhibition of tumor growth using feedback linearization [C] . Szeles A., Drexler D.A., Sapi J., IEEE Annual Conference on Decision and Control . 2013

机译：使用反馈线性化的基于模型的血管生成抑制肿瘤生长
5. A Phase 1/2 Study of Ixazomib as a Replacement for Bortezomib or Carfilzomib for Multiple Myeloma Patients Recently Relapsed or Refractory to Their Last Combination Regimen Containing Either Bortezomib or Carfilzomib [D] . Forouzan, Eli. 2020

机译：Ixazomib的第1/2期作为替代品髓鞘或胭脂瘤患者的替代品的替代物，最近对含有Bortezomib或Carfilzomib的最后组合方案复发或难治
6. A Tumor Growth Inhibition Model Based on M‐Protein Levels in Subjects With Relapsed/Refractory Multiple Myeloma Following Single‐Agent Carfilzomib Use [O] . F Jonsson, Y Ou, L Claret, 2015

机译：单剂卡非佐米后复发/难治性多发性骨髓瘤患者基于M蛋白水平的肿瘤生长抑制模型
7. A tumor growth inhibition model based on M-protein levels in subjects with relapsed/refractory multiple myeloma following single-agent carfilzomib use [O] . Jonsson F., Ou Y., Claret L., 2015

机译：单药卡非佐米使用后复发/难治性多发性骨髓瘤患者基于M蛋白水平的肿瘤生长抑制模型

A TUMOR GROWTH INHIBITION MODEL BASED ON M-PROTEIN LEVELS IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA FOLLOWING SINGLE-AGENT CARFILZOMIB USE

著录项

引文网络

相似文献

相关主题

期刊订阅